"Hemophilia A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The classic hemophilia resulting from a deficiency of factor VIII. It is an inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhage.
Descriptor ID |
D006467
|
MeSH Number(s) |
C15.378.100.100.500 C15.378.100.141.500 C15.378.463.500 C16.320.099.500
|
Concept/Terms |
Hemophilia A- Hemophilia A
- Hemophilia As
- Hemophilia, Classic
- Hemophilia
- Hemophilia A, Congenital
- Congenital Hemophilia A
- Congenital Hemophilia As
- Hemophilia As, Congenital
- Classic Hemophilia
- Classic Hemophilias
- Hemophilias, Classic
- Haemophilia
Autosomal Hemophilia A- Autosomal Hemophilia A
- As, Autosomal Hemophilia
- Autosomal Hemophilia As
- Hemophilia A, Autosomal
- Hemophilia As, Autosomal
Factor VIII Deficiency- Factor VIII Deficiency
- Factor 8 Deficiency, Congenital
- Factor VIII Deficiency, Congenital
- Deficiency, Factor VIII
|
Below are MeSH descriptors whose meaning is more general than "Hemophilia A".
Below are MeSH descriptors whose meaning is more specific than "Hemophilia A".
This graph shows the total number of publications written about "Hemophilia A" by people in this website by year, and whether "Hemophilia A" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2001 | 1 | 0 | 1 |
2004 | 1 | 1 | 2 |
2006 | 1 | 0 | 1 |
2007 | 2 | 0 | 2 |
2008 | 2 | 0 | 2 |
2011 | 1 | 1 | 2 |
2012 | 1 | 0 | 1 |
2016 | 4 | 1 | 5 |
2017 | 5 | 0 | 5 |
2018 | 3 | 0 | 3 |
2020 | 5 | 0 | 5 |
2021 | 2 | 0 | 2 |
2022 | 1 | 0 | 1 |
2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hemophilia A" by people in Profiles.
-
Effects of PK-guided prophylaxis on clinical outcomes and FVIII consumption for patients with moderate to severe Haemophilia A. Haemophilia. 2023 Sep; 29(5):1234-1242.
-
A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia. Br J Haematol. 2023 01; 200(2):229-239.
-
Using an educational intervention to assess and improve disease-specific knowledge and health literacy and numeracy in adolescents and young adults with haemophilia A and B. Haemophilia. 2021 Mar; 27(2):229-236.
-
Identified unmet needs and proposed solutions in mild-to-moderate haemophilia: A summary of opinions from a roundtable of haemophilia experts. Haemophilia. 2021 Jan; 27 Suppl 1:25-32.
-
Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis. Thromb Haemost. 2021 08; 121(8):1079-1086.
-
Hemophilia: A Review of Perioperative Management for Cardiac Surgery. J Cardiothorac Vasc Anesth. 2022 01; 36(1):246-257.
-
A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients. J Manag Care Spec Pharm. 2020 Oct; 26(10):1258-1265.
-
Comparing Physician and Patient Perspectives on Prophylactic Treatment with BAY?94-9027 for Severe Haemophilia?A: A Post Hoc Analysis. Adv Ther. 2020 06; 37(6):2763-2776.
-
Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products. J Manag Care Spec Pharm. 2020 Apr; 26(4):504-512.
-
Blood-induced bone loss in murine hemophilic arthropathy is prevented by blocking the iRhom2/ADAM17/TNF-a pathway. Blood. 2018 09 06; 132(10):1064-1074.